E-mail: lling@51chemall.com
Contact Us
Wuhan Lihe New Chemical Materials Co.,Ltd
Add: Room 1801, Building B, Wuhan University Of Technology Entrepreneur Incubator, Hongshan, Wuhan, Hubei, China
Home > News > Content
Two Chinese Independent Research And Development Of PD-1 Antibody Drugs Have Been Listed
Jan 08, 2019

According to the news published on the website of the State Drug Administration, Xindeli monoclonal antibody injection is a kind of innovative medicine independently researched and developed by Chinese enterprises and possesses completely independent intellectual property rights. It has been supported by the national major new drug creation and key research and development plan projects. The review and approval process was approved for the treatment of relapsed or refractory classic Hodgkin's lymphoma undergoing second-line chemotherapy.


Hodgkin's lymphoma is a rare B-cell malignant lymphoma that occurs mostly in young people between the ages of 20 and 40. Although its early treatment effect is better and the cure rate is higher, there is still about 20% recurrence rate after first-line treatment. Relapsed or refractory classic Hodgkin's lymphoma currently lacks effective treatment methods and means.


It is understood that, unlike traditional chemotherapy and targeted therapy, PD-1 antibody drugs can kill tumors by overcoming the immune suppression of patients and re-activating their own immune cells. Clinical data show that sindolib monoclonal injection can bring significant clinical benefit to patients with relapsed or refractory classic Hodgkin's lymphoma, and the safety risk is controllable.


It is reported that domestic companies are enthusiastic about the research and development of innovative biological products. More than 200 anti-tumor drugs or biosimilar drugs have been approved for clinical use. On December 17, 2018, the State Drug Administration conditionally approved the first domestic PD-1 antibody drug, Treiprilizumab injection, for the treatment of local progression or metastatic melanin after failure of previous standard treatment. tumor.

Copyright © Wuhan Lihe New Chemical Materials Co.,Ltd All Rights Reserved.